A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Hoffmann-La Roche
Nuvectis Pharma, Inc.
Dutch Society of Physicians for Pulmonology and Tuberculosis
AstraZeneca
Eli Lilly and Company
AstraZeneca
Maia Biotechnology
Plexium, Inc.
Maia Biotechnology
EMD Serono